Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
Follow ZLAB by emailGet an email when ZLAB pushes back a promised milestone, files for a stock offering or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about ZLAB, unsubscribe in one click. Privacy
📣 What ZLAB Says Is Next
first half of 2027 · “Initial clinical data from the MAD portion expected in the first half of 2027.”
Company press release, Aug 6, 2026 · SEC filing
in 2026 · “Zai Lab participated in the global Phase 3 RAINIER study in Greater China. 3 Anticipated Major Milestones in 2026 and the First Half of 2027 Global Pipeline Expected Clinical Developments and Data Readouts Zocilurtatug Pelitecan (zoci, DLL3-Targeting ADC; formerly ZL-1310)”
Company press release, Aug 6, 2026 · SEC filing
second half of 2026 · “ZL-1503 (IL-13/IL-31Rα): Completed enrollment in the single ascending dose (SAD) portion of the Phase 1/1b study of ZL-1503 in healthy volunteers, with initial PK, PD, safety and immunogenicity data expected in the second half of 2026.”
Company press release, Aug 6, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Get the full ZLAB picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for ZLAB and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.